Serina Therapeutics
About: Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Employees: 13
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
4% more funds holding
Funds holding: 24 [Q3] → 25 (+1) [Q4]
0.21% more ownership
Funds ownership: 3.38% [Q3] → 3.59% (+0.21%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
20% less capital invested
Capital invested by funds: $2.01M [Q3] → $1.6M (-$408K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jones Trading Justin Walsh 27% 1-year accuracy 3 / 11 met price target | 74%upside $11 | Buy Initiated | 11 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SER published over the past 30 days









